These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 3904378)
1. Secondary prevention and lipid lowering: results and implications. Detre KM; Levy RI; Kelsey SF; Epstein SE; Brensike JF; Passamani ER; Richardson JM; Loh IK; Stone NJ; Aldrich RF Am Heart J; 1985 Nov; 110(5):1123-7. PubMed ID: 3904378 [TBL] [Abstract][Full Text] [Related]
2. The influence of changes in lipid values induced by cholestyramine and diet on progression of coronary artery disease: results of NHLBI Type II Coronary Intervention Study. Levy RI; Brensike JF; Epstein SE; Kelsey SF; Passamani ER; Richardson JM; Loh IK; Stone NJ; Aldrich RF; Battaglini JW Circulation; 1984 Feb; 69(2):325-37. PubMed ID: 6360415 [TBL] [Abstract][Full Text] [Related]
3. Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: results of the NHLBI Type II Coronary Intervention Study. Brensike JF; Levy RI; Kelsey SF; Passamani ER; Richardson JM; Loh IK; Stone NJ; Aldrich RF; Battaglini JW; Moriarty DJ Circulation; 1984 Feb; 69(2):313-24. PubMed ID: 6360414 [TBL] [Abstract][Full Text] [Related]
4. National Heart, Lung, and Blood Institute type II Coronary Intervention Study: design, methods, and baseline characteristics. Brensike JF; Kelsey SF; Passamani ER; Fisher MR; Richardson JM; Loh IK; Stone NJ; Aldrich RF; Battaglini JW; Moriarty DJ; Myrianthopoulos MB; Detre KM; Epstein SE; Levy RI Control Clin Trials; 1982 Jun; 3(2):91-111. PubMed ID: 6749427 [TBL] [Abstract][Full Text] [Related]
5. Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas' Atherosclerosis Regression Study (STARS). Watts GF; Lewis B; Brunt JN; Lewis ES; Coltart DJ; Smith LD; Mann JI; Swan AV Lancet; 1992 Mar; 339(8793):563-9. PubMed ID: 1347091 [TBL] [Abstract][Full Text] [Related]
6. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA; 1984 Jan; 251(3):351-64. PubMed ID: 6361299 [TBL] [Abstract][Full Text] [Related]
7. Effects of combination cholestyramine-neomycin treatment on plasma lipoprotein concentrations in type II hyperlipoproteinemia. Hoeg JM; Maher MB; Bailey KR; Zech LA; Gregg RE; Sprecher DL; Brewer HB Am J Cardiol; 1985 May; 55(11):1282-6. PubMed ID: 3887883 [TBL] [Abstract][Full Text] [Related]
8. Report on the Lipid Research Clinic trials. Levy RI Eur Heart J; 1987 Aug; 8 Suppl E():45-53. PubMed ID: 3315677 [TBL] [Abstract][Full Text] [Related]
9. Lipid Research Clinics Coronary Primary Prevention Trial: results and implications. Rifkind BM Am J Cardiol; 1984 Aug; 54(5):30C-34C. PubMed ID: 6382999 [TBL] [Abstract][Full Text] [Related]
10. The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA; 1984 Jan; 251(3):365-74. PubMed ID: 6361300 [TBL] [Abstract][Full Text] [Related]
11. Dietary and other correlates of changes in total and low density lipoprotein cholesterol in hypercholesterolemic men: the lipid research clinics coronary primary prevention trial. Glueck CJ; Gordon DJ; Nelson JJ; Davis CE; Tyroler HA Am J Clin Nutr; 1986 Oct; 44(4):489-500. PubMed ID: 3532756 [TBL] [Abstract][Full Text] [Related]
12. Changing perspectives in the prevention of coronary artery disease. Levy RI Am J Cardiol; 1986 May; 57(14):17G-26G. PubMed ID: 3087152 [TBL] [Abstract][Full Text] [Related]
13. Role of risk factor management in progression and regression of coronary and femoral artery atherosclerosis. Glueck CJ Am J Cardiol; 1986 May; 57(14):35G-41G. PubMed ID: 3521250 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of triple therapy (fluvastatin-bezafibrate-cholestyramine) for severe familial hypercholesterolemia. Leitersdorf E; Muratti EN; Eliav O; Peters TK Am J Cardiol; 1995 Jul; 76(2):84A-88A. PubMed ID: 7604807 [TBL] [Abstract][Full Text] [Related]
15. Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and "normal" cholesterol levels. A randomized, placebo-controlled trial. Harvard Atherosclerosis Reversibility Project (HARP) Study Group. Pasternak RC; Brown LE; Stone PH; Silverman DI; Gibson CM; Sacks FM Ann Intern Med; 1996 Oct; 125(7):529-40. PubMed ID: 8815751 [TBL] [Abstract][Full Text] [Related]
16. Pre-entry characteristics of participants in the Lipid Research Clinics' Coronary Primary Prevention Trial. J Chronic Dis; 1983; 36(6):467-79. PubMed ID: 6863470 [TBL] [Abstract][Full Text] [Related]
17. NHLBI workshop on the Lipid Research Clinics Coronary Primary Prevention Trial. Arteriosclerosis; 1985; 5(4):397-403. PubMed ID: 3893403 [No Abstract] [Full Text] [Related]
18. Effect on coronary atherosclerosis of decrease in plasma cholesterol concentrations in normocholesterolaemic patients. Harvard Atherosclerosis Reversibility Project (HARP) Group. Sacks FM; Pasternak RC; Gibson CM; Rosner B; Stone PH Lancet; 1994 Oct; 344(8931):1182-6. PubMed ID: 7934538 [TBL] [Abstract][Full Text] [Related]
19. A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events. Whitney EJ; Krasuski RA; Personius BE; Michalek JE; Maranian AM; Kolasa MW; Monick E; Brown BG; Gotto AM Ann Intern Med; 2005 Jan; 142(2):95-104. PubMed ID: 15657157 [TBL] [Abstract][Full Text] [Related]